Results 251 to 260 of about 54,679 (264)

Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma

European Journal of Cancer, 2017
Lisa Zimmer, Susmitha Apuri, Zeynep Eroglu   +2 more
exaly  

Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma

Annals of the New York Academy of Sciences, 2013
James P Allison, Walter J Urba, Caroline Robert   +2 more
exaly  

Ipilimumab and radiation therapy for melanoma brain metastases

Cancer Medicine, 2013
Ann W Silk, Christina I Tsien, Christopher D Lao   +2 more
exaly  

Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab

Annals of Oncology, 2016
Paolo A Ascierto, Jacopo Pigozzo, Michele Del Vecchio   +2 more
exaly  

Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma

Annals of Oncology, 2013
Riccardo Danielli, V Chiarion-Sileni, Jacopo Pigozzo   +2 more
exaly  

Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial

Annals of Oncology, 2013
Martin Reck, Igor Bondarenko, A Luft
exaly  

Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials

Annals of Oncology, 2013
J D Wolchok, J S Weber, Michele Maio
exaly  

Patterns of onset and resolution of immune‐related adverse events of special interest with ipilimumab

Cancer, 2013
Reinhard Dummer, Veerle De Pril, Celeste Lebbe   +2 more
exaly  

Ipilimumab

Reactions Weekly, 2023
openaire   +1 more source

Ipilimumab-Associated Colitis: CT Findings

American Journal of Roentgenology, 2013
Kyung Won Kim, Nikhil H Ramaiya, Atul B Shinagare   +2 more
exaly